Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

723
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
723
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

777
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
777
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.6K
The pathophysiology of pneumonia involves the following steps:
2.6K
Pneumonia IV: Management01:28

Pneumonia IV: Management

751
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
751
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

475
Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
475

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes.

Nature communications·2026
Same author

Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer.

Signal transduction and targeted therapy·2026
Same author

Innovation in intensive care: a framework to turn ideas and concepts into actionable solutions.

Intensive care medicine·2026
Same author

Think beyond the standard: anti-MRSA options in community-acquired pneumonia - Authors' reply.

Lancet (London, England)·2026
Same author

Defining the bellwether procedures and processes for global trauma care: an international Delphi study.

BMJ global health·2026
Same author

Arterial lines: is the pulse still strong?

Anaesthesia·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.6K

Community-acquired pneumonia.

Luis Felipe Reyes1, Andrew Conway Morris2, Cristian Serrano-Mayorga3

  • 1Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chía, Colombia; Clinica Universidad de La Sabana, Chía, Colombia; International Severe Acute Respiratory and Emerging Infection Consortium, Pandemic Sciences Institute, University of Oxford, Oxford, UK.

Lancet (London, England)
|October 19, 2025
PubMed
Summary
This summary is machine-generated.

Community-acquired pneumonia (CAP) poses a global health threat with long-term complications. Advances in diagnostics and personalized treatments, including nucleic acid amplification tests (NAATs), offer improved outcomes for CAP management.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.7K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.5K

Related Experiment Videos

Last Updated: Jan 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.6K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.7K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.5K

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Public Health

Background:

  • Community-acquired pneumonia (CAP) is a significant global health issue, particularly impacting vulnerable groups.
  • Previously viewed as acute, CAP is now understood to have long-term consequences like cardiovascular events and cognitive decline.

Purpose of the Study:

  • To review current understanding and future directions in CAP management.
  • To highlight the evolving role of diagnostics and personalized therapies in combating CAP.

Main Methods:

  • Literature review focusing on recent advancements in CAP diagnostics and treatment.
  • Analysis of the integration of new technologies like nucleic acid amplification tests (NAATs) and lung ultrasound.
  • Evaluation of the role of adjunctive therapies and preventive strategies.

Main Results:

  • Nucleic acid amplification tests (NAATs) and point-of-care lung ultrasound enable rapid pathogen detection and tailored treatment.
  • Uncertainties persist regarding the clinical utility of NAATs, lung ultrasounds, and serum biomarkers.
  • The roles of adjunctive therapies like corticosteroids and immunomodulators require further definition.

Conclusions:

  • Comprehensive CAP management necessitates personalized treatment, post-acute rehabilitation, and cardiovascular screening.
  • Integrating advanced diagnostics and tailored therapies is crucial for improving outcomes and reducing the global burden of CAP.
  • Strengthening preventive measures, such as vaccination, remains essential.